Caredx, Inc. annual report, FY2023

CareDx, Inc. — FY2023 Form 10-K

Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the provided filing text does not give a clear standalone Q4 income statement or other Q4-only financial results. CareDx is a transplant-focused precision medicine company offering diagnostic testing, transplant-related products, and patient and digital solutions.

Financial performance

Metric	FY2023	FY2022	Change
Revenue	$280.3 million	$321.8 million	Down 13%
Operating loss	$203.4 million	$77.2 million	Loss increased $126.1 million
Net loss	$190.3 million	$76.6 million	Loss increased $113.7 million
Net loss per share, diluted	$3.54	$1.44	Loss per share increased
Cash used in operating activities	$18.4 million	$25.2 million	Cash use decreased $6.9 million

• Revenue mix: testing services $209.7 million (75% of revenue), products $33.5 million (12%), and patient and digital solutions $37.1 million (13%).
• Testing-services revenue declined 20% to $209.7 million, primarily from lower Medicare revenue following new billing requirements. Product revenue rose 15%, and patient and digital solutions revenue rose 29%.
• Approximate gross profit was $178.3 million, or 63.6% of revenue, based on reported revenue less the three reported cost-of-revenue categories. The filing does not present this as a named consolidated gross-margin measure.
• Operating expenses were $483.7 million, including a $96.3 million Natera patent-litigation charge and $2.3 million of restructuring costs. Excluding the litigation charge, operating loss would be approximately $107.1 million, calculated from reported figures.
• Research and development expense was $81.9 million, down 9%; sales and marketing was $83.3 million, down 13%; and general and administrative expense was $117.9 million, up 17%.

Liquidity, cash flow and balance sheet

• At year-end, cash, cash equivalents and marketable securities totaled $235.4 million, compared with $293.1 million in 2022. Cash and cash equivalents alone were $82.2 million; marketable securities were $153.2 million.
• Current assets were $313.7 million and current liabilities were $78.1 million. The company reported no debt outstanding.
• Cash used in operating activities was $18.4 million. Investing activities provided $40.4 million, primarily reflecting net marketable-security maturities; financing activities used $29.6 million, including $27.5 million for share repurchases.
• Total liabilities increased to $205.5 million from $112.1 million, principally reflecting the $96.3 million Natera patent verdict liability recorded at year-end. Stockholders’ equity declined to $261.3 million from $430.9 million.
• Management said existing cash and expected cash from operations and agreements should cover anticipated cash needs for the next 12 months, while noting future financing may be needed. A $250 million shelf registration statement is available.

Material developments, outlook and risks

• Medicare billing and reimbursement: New MolDX billing articles affected Medicare claims for AlloSure Kidney, AlloSure Heart, AlloMap Heart and AlloSure Lung. CareDx paused submissions for about 3,200 AlloSure Kidney tests from March 7–31, 2023; it later received payment and recognized about $7.8 million of the approximately $8.9 million initially unrecognized. The company says it disputes aspects of the new requirements and updated billing processes. Medicare represented 53% of testing-services revenue; the filing separately reports Medicare-billed revenue at 40% of total revenue.
• Natera litigation: A January 26, 2024 jury verdict found infringement of one Natera patent and awarded approximately $96.3 million for AlloSure and AlloSeq sales. CareDx recorded the amount as a 2023 litigation expense and liability. It intends to seek judicial review and contest ongoing-infringement claims; an injunction may also be sought. In separate false-advertising litigation, a jury had awarded CareDx $44.9 million, but the court did not uphold the monetary damages; appeals are ongoing. The court issued an injunction against Natera’s specified claims.
• Other legal and regulatory matters: The SEC notified CareDx in September 2023 that it had concluded its investigation and did not intend to recommend enforcement action against the company. The DOJ False Claims Act investigation concerning kidney testing and phlebotomy practices remained unresolved; CareDx says it is cooperating. Certain state licensing matters also remain in process.
• Controls and audit: Management and Deloitte concluded internal control over financial reporting was ineffective at December 31, 2023 because of material weaknesses in IT general controls, purchase-order approval, and components of the COSO control framework. Deloitte issued an adverse opinion on internal control, while giving an unqualified opinion on the financial statements. Disclosure controls were also deemed ineffective. Management reported remediation work underway, but the weaknesses were not remediated by year-end.
• Business and regulatory risks: CareDx reports a history of losses and expects continued losses in coming years. Its results are sensitive to Medicare coverage, payer collection and billing requirements, adoption of its tests, competition, litigation, FDA oversight of laboratory-developed tests, and reliance on key suppliers. The filing notes a proposed FDA rule to phase out general enforcement discretion for LDTs; its final form and timing are uncertain.
• Outlook: No specific FY2024 revenue or earnings guidance is provided in the supplied text. CareDx disclosed that it had previously withdrawn FY2023 revenue guidance.

Most important facts for investors to verify

• Current status and financial exposure of the Natera patent verdict, including appeals, potential injunctions, and any effect on AlloSure or AlloSeq operations.
• Final Medicare LCD or billing requirements, the claims CareDx can submit under them, and resulting test volume, collections, and revenue.
• Progress and independent validation of remediation efforts for the material weaknesses in financial reporting controls.
• Whether operating cash use, losses, and the $235.4 million liquidity balance remain consistent with management’s 12-month funding assessment.
• Whether testing-services revenue stabilizes and growth in products and digital solutions offsets continued pressure in the testing business.